CEO ENDOMET (The Collider Programme)

Job description

ENDOMET | Switching On Endogenous Energy CEO & Co-Founder Opportunity | Biotech | Rare Diseases & Womens Health Are you looking for a high-impact entrepreneurial opportunity to build a science-driven biotech spin-off addressing rare mitochondrial diseases and female reproductive health? ENDOMET, a deep-tech biotech project backed by the University of Granada, is developing MVP11, a first-in-class small molecule that restores mitochondrial energy by activating endogenous Coenzyme Q (CoQ) biosynthesis. The project is seeking an entrepreneurial CEO to join the founding team and lead the creation of the spin-off. About ENDOMET: A large number of frequent and rare diseases are characterized by CoQ deficiency, leading to impaired mitochondrial energy production. Current standard care relies on exogenous CoQ10 supplementation, which underperforms due to poor bioavailability, limited delivery to target tissues and insufficient mitochondrial impact. ENDOMET has developed a small molecule designed to reach mitochondria and stimulate endogenous CoQ biosynthesis, enabling cells to restore their own energy production. This approach represents a true therapeutic restoration, rather than suppleme...